Literature DB >> 19539527

The adenosinergic immunomodulatory drugs.

Akio Ohta1, Michail Sitkovsky.   

Abstract

Hypoxia-driven increase of extracellular adenosine in local tissue microenvironments of inflamed and cancerous tissues plays a critical role in the regulation of tissue destruction by activated immune cells. Accumulated data suggest that injection or consumption of A2A adenosine receptor (A2AR) antagonists may represent a drug treatment that diminishes adenosine-mediated immunosuppression. Since this, in turn, enhances the immune response, inhibition of adenosine-A2AR signaling may be a promising approach to enhance anti-tumor or anti-pathogen immune response. Patients with disorders characterized by excessive inflammation may be at risk to A2AR antagonists (e.g. caffeine) because of the effect to increase inflammatory damage secondary to enhanced immunity. On the other hand, enhancement of hypoxia-adenosinergic immunomodulatory pathways may be beneficial to prevent inflammatory tissue destruction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19539527      PMCID: PMC2756083          DOI: 10.1016/j.coph.2009.05.005

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  46 in total

1.  A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice.

Authors:  J F Chen; Z Huang; J Ma; J Zhu; R Moratalla; D Standaert; M A Moskowitz; J S Fink; M A Schwarzschild
Journal:  J Neurosci       Date:  1999-11-01       Impact factor: 6.167

2.  A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice.

Authors:  Tobias Eckle; Almut Grenz; Stefanie Laucher; Holger K Eltzschig
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

3.  Neutrophil-epithelial crosstalk at the intestinal lumenal surface mediated by reciprocal secretion of adenosine and IL-6.

Authors:  S V Sitaraman; D Merlin; L Wang; M Wong; A T Gewirtz; M Si-Tahar; J L Madara
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

Review 4.  Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia.

Authors:  Michail V Sitkovsky; Jorgen Kjaergaard; Dmitriy Lukashev; Akio Ohta
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

5.  A2B adenosine receptor gene deletion attenuates murine colitis.

Authors:  Vasantha L Kolachala; Matam Vijay-Kumar; Guillaiume Dalmasso; Dan Yang; Joel Linden; Lixin Wang; Andrew Gewirtz; Katya Ravid; Didier Merlin; Shanthi V Sitaraman
Journal:  Gastroenterology       Date:  2008-05-21       Impact factor: 22.682

6.  Pharmacological blockade of A2A receptors prevents dermal fibrosis in a model of elevated tissue adenosine.

Authors:  Patricia Fernández; Sean Trzaska; Tuere Wilder; Luis Chiriboga; Michael R Blackburn; Bruce N Cronstein; Edwin S L Chan
Journal:  Am J Pathol       Date:  2008-05-08       Impact factor: 4.307

7.  HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak.

Authors:  Julio C Morote-Garcia; Peter Rosenberger; Johannes Kuhlicke; Holger K Eltzschig
Journal:  Blood       Date:  2008-02-28       Impact factor: 22.113

8.  Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice.

Authors:  Ailin Bai; Eileen Higham; Herman N Eisen; K Dane Wittrup; Jianzhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-22       Impact factor: 11.205

Review 9.  Immune therapy for cancer.

Authors:  Michael Dougan; Glenn Dranoff
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

10.  Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor.

Authors:  T Vang; K M Torgersen; V Sundvold; M Saxena; F O Levy; B S Skålhegg; V Hansson; T Mustelin; K Taskén
Journal:  J Exp Med       Date:  2001-02-19       Impact factor: 14.307

View more
  18 in total

Review 1.  Modifying radiation damage.

Authors:  Kwanghee Kim; William H McBride
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

2.  Adenosine and its receptors as therapeutic targets: An overview.

Authors:  Sakshi Sachdeva; Monika Gupta
Journal:  Saudi Pharm J       Date:  2012-06-23       Impact factor: 4.330

3.  Schwann Cells Metabolize Extracellular 2',3'-cAMP to 2'-AMP.

Authors:  Jonathan D Verrier; Patrick M Kochanek; Edwin K Jackson
Journal:  J Pharmacol Exp Ther       Date:  2015-05-21       Impact factor: 4.030

Review 4.  Inflammation, pain, and pressure--purinergic signaling in oral tissues.

Authors:  J C Lim; C H Mitchell
Journal:  J Dent Res       Date:  2012-10-04       Impact factor: 6.116

5.  Adenosine modulates Toll-like receptor function: basic mechanisms and translational opportunities.

Authors:  Melanie R Power Coombs; Mirjam E Belderbos; Leighanne C Gallington; Louis Bont; Ofer Levy
Journal:  Expert Rev Anti Infect Ther       Date:  2011-02       Impact factor: 5.091

6.  Adenosine and cAMP signalling skew human dendritic cell differentiation towards a tolerogenic phenotype with defective CD8(+) T-cell priming capacity.

Authors:  John Challier; Denis Bruniquel; Andrew K Sewell; Bruno Laugel
Journal:  Immunology       Date:  2013-04       Impact factor: 7.397

7.  Fall in oxygen tension of culture medium stimulates the adenosinergic signalling of a human T cell line.

Authors:  Youlet By; Laurent Jacquin; Frédéric Franceschi; Josée-Martine Durand-Gorde; Jocelyne Condo; Pierre Michelet; Régis Guieu; Jean Ruf
Journal:  Purinergic Signal       Date:  2012-02-14       Impact factor: 3.765

8.  Transcriptomic effects of adenosine 2A receptor deletion in healthy and endotoxemic murine myocardium.

Authors:  Kevin J Ashton; Melissa E Reichelt; S Jamal Mustafa; Bunyen Teng; Catherine Ledent; Lea M D Delbridge; Polly A Hofmann; R Ray Morrison; John P Headrick
Journal:  Purinergic Signal       Date:  2016-09-30       Impact factor: 3.765

9.  Endogenous Inhibitors of Kidney Inflammation.

Authors:  Jessica Trostel; Gabriela E Garcia
Journal:  J Nephrol Res       Date:  2015-10

10.  The guanosine-adenosine interaction exists in vivo.

Authors:  Edwin K Jackson; Zaichuan Mi
Journal:  J Pharmacol Exp Ther       Date:  2014-07-07       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.